机器人主动脉瓣置换与经导管主动脉瓣置换的倾向匹配分析
本研究对605例(2017-2023年)由同一结构性心脏病团队管理的患者中174例机器人主动脉瓣置换(RAVR)与431例经导管主动脉瓣置换(TAVR)进行倾向匹配,评估院内及1年结局。288例低至中危(STS预测死亡风险<8%)患者匹配为144对,两组院内及30天死亡率相似;结论提示RAVR在低中危症状性重度主动脉瓣狭窄患者中可能为安全有效的微创替代方案。
要点
- 低中危患者中RAVR与TAVR的院内及30天死亡率相似。
- TAVR的1年死亡率(12.5% vs 1.4%)和大于轻度瓣周漏(32.6% vs 2.3%)显著更高。
核心结论
- 在低至中危重度症状性主动脉瓣狭窄患者中,RAVR较TAVR起搏器和血管并发症更少,1年瓣周漏和死亡率更低。
- RAVR可能为TAVR提供安全有效的微创替代选择。
研究设计与样本
- 回顾性倾向匹配分析,纳入2017-2023年同一结构性心脏病团队管理的605例患者(174例RAVR,431例TAVR)。
- 匹配后288例低至中危(STS预测死亡风险<8%)患者分为144例RAVR与144例TAVR两组,评估院内及1年结局。
主要发现
- 两组院内和30天死亡率相似。
- TAVR组1年死亡率12.5% vs 1.4%(P<0.0001),大于轻度瓣周漏32.6% vs 2.3%(P<0.0001)。
- RAVR组8例(5.6%)因血胸清除需再次手术;TAVR组2例转开胸(心脏骤停和冠状动脉闭塞)。
- 30天输血、心房颤动或1年平均瓣膜压差无差异。
关键数值与推荐
- 低至中危定义:STS预测死亡风险<8%。
- TAVR组1年死亡率(12.5% vs 1.4%,P<0.0001)、大于轻度瓣周漏(32.6% vs 2.3%,P<0.0001)。
临床怎么用
- 对于低至中危重度症状性主动脉瓣狭窄,RAVR可考虑作为TAVR的微创替代,尤其关注起搏器及血管并发症风险时。
- TAVR术后需注意起搏器植入、血管并发症及瓣周漏的随访。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current evidence supports equipoise between surgical aortic valve replacement (AVR) and transcatheter AVR (TAVR) for the management of symptomatic severe aortic stenosis (AS). The optimal interventional management for lower-risk patients is controversial. Minimally invasive robotic AVR (RAVR) was developed as a potential option. METHODS: A total of 605 consecutive patients (2017-2023) managed by the identical structural heart team, 174 RAVR and 431 TAVR, were propensity matched and evaluated for in-hospital and 1-year outcomes. RESULTS: There were 288 low- to intermediate-risk (The Society of Thoracic Surgeons predicted risk of mortality <8%) patients matched in 2 well-balanced groups (144 RAVR vs 144 TAVR). In-hospital and 30-day mortality were similar. There were 2 conversions to sternotomy in the TAVR group (cardiac arrest and coronary occlusion) and none in the RAVR group. Eight RAVR patients (5.6%) required reoperation for hemothorax evacuation. TAVR was associated with higher new pacemaker (11 vs 3, P = .028) and major vascular complications (13 vs 0, P < .0001), and a higher postprocedural stroke trend (6 vs 1, P = .056). There was no difference in 30-day transfusions, atrial fibrillation, or 1-year mean valve gradients. However, 1-year mortality (12.5% vs 1.4%, P < .0001) and paravalvular leak greater than mild (32.6% vs 2.3%, P < 0.0001) were significantly higher in TAVR. CONCLUSIONS: These data highlight lower pacemaker and vascular complications, as well as less 1-year paravalvular leak and mortality with RAVR compared with TAVR. RAVR may provide a safe and effective minimally invasive alternative to TAVR for low- and intermediate-risk patients presenting with severe symptomatic AS.
引用
- Jagadeesan V, Mehaffey JH, Darehzereshki A, et al. Robotic Aortic Valve Replacement vs Transcatheter Aortic Valve Replacement: A Propensity-Matched Analysis. Ann Thorac Surg. 2024. PMID: 39481823. doi:10.1016/j.athoracsur.2024.10.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。